C4 Therapeutics, Inc. (CCCC) Operating Margin
- Operating margin · 12 months: Value -318.97%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -318.97% | Operating income / revenue. Period ending 2026-06-30. $-111.77M ÷ $35.04M × 100 ≈ -318.97% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -111.77M USD | Operating Income (Loss) |
| Revenue | 35.04M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 100.05M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-111.77M | $35.04M | (m) | $100.05M | (m) | -318.97% |
| 2026-03-31 | $-113.84M | $34.86M | (m) | $101.77M | (m) | -326.56% |
| 2025-12-31 | $-115.22M | $35.95M | (m) | $104.24M | (m) | -320.53% |
| 2025-09-30 | $-129.79M | $30.11M | (m) | $111.77M | (m) | -431.07% |
| 2025-06-30 | $-123.62M | $34.24M | (m) | $117.62M | (m) | -361.03% |
| 2025-03-31 | $-116.56M | $39.78M | (m) | $115.18M | (m) | -292.99% |
| 2024-12-31 | $-119.61M | $35.58M | (m) | $110.64M | (m) | -336.15% |
| 2024-09-30 | $-119.33M | $33.67M | (m) | $108.52M | (m) | -354.44% |
| 2024-06-30 | $-118.90M | $29.38M | (m) | $105.02M | (m) | -404.71% |
| 2024-03-31 | $-135.02M | $20.04M | (m) | $111.20M | (m) | -673.90% |
| 2023-12-31 | $-139.03M | $20.76M | (m) | $117.71M | (m) | -669.84% |
| 2023-09-30 | $-139.90M | $20.35M | (m) | $117.97M | (m) | -687.49% |
| 2023-06-30 | $-144.58M | $16.03M | (m) | $119.28M | (m) | -901.86% |
| 2023-03-31 | $-134.39M | $27.20M | (m) | $120.68M | (m) | -494.07% |
| 2022-12-31 | $-129.53M | $31.10M | (m) | $117.84M | (m) | -416.56% |
| 2022-09-30 | $-106.50M | (m) | (m) | $113.74M | (m) | (m) |
| 2022-06-30 | $-98.26M | (m) | (m) | $108.38M | (m) | (m) |
| 2022-03-31 | $-92.99M | (m) | (m) | $100.34M | (m) | (m) |
| 2021-12-31 | $-82.13M | (m) | (m) | $94.67M | (m) | (m) |
| 2021-09-30 | $-85.78M | (m) | (m) | $88.55M | (m) | (m) |
| 2021-06-30 | $-79.88M | (m) | (m) | $88.18M | (m) | (m) |
| 2021-03-31 | $-68.62M | (m) | (m) | $82.65M | (m) | (m) |
| 2020-12-31 | $-60.45M | (m) | (m) | $78.44M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-35.45M | (m) | (m) | $48.06M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |